Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JNJ
- Rev/Share 37.4631
- Book/Share 32.4389
- PB 5.716
- Debt/Equity 0.6469
- CurrentRatio 1.0059
- ROIC 0.1216
- MktCap 446554193646.0
- FreeCF/Share 6.7781
- PFCF 27.2339
- PE 19.7939
- Debt/Assets 0.2625
- DivYield 0.0274
- ROE 0.3039
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | JNJ | Guggenheim | Neutral | Buy | -- | $206 | Sept. 23, 2025 |
| Upgrade | JNJ | Erste Group | Hold | Buy | -- | -- | July 23, 2025 |
| Downgrade | JNJ | Leerink Partners | Outperform | Market Perform | -- | $153 | May 13, 2025 |
| Resumed | JNJ | BofA Securities | -- | Neutral | -- | $166 | Dec. 10, 2024 |
News
Why JNJ Stock Defines Shareholder Supremacy In Healthcare
Published: September 30, 2025 by: Forbes
Sentiment: Positive
Over the past ten years, Johnson & Johnson (NYSE: JNJ) has delivered an impressive $157 Bil back to its investors through cash distributions via dividends and buybacks. This commitment to shareholder value has translated into exceptional market performance in 2025, with the stock delivering a remarkable 26% year-to-date return, significantly outpacing the broader healthcare sector and demonstrating the defensive strength that has made JNJ a cornerstone holding for income-focused investors.
Read More
3 Ultra-Safe Dividend Stocks to Buy Now, If You're Concerned About Volatility Ahead
Published: September 30, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors who find themselves awake at night thinking about their portfolios, fear not.
Read More
Johnson & Johnson (JNJ) Could Be a Great Choice
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Read More
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Read More
Should You Invest in Johnson & Johnson (JNJ) Based on Bullish Wall Street Views?
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
J&J Adds $63B in Market Cap in 3 Months: Time to Buy the Stock?
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J shares gain 17.7% in three months, adding $63B to its market cap. Technical and pipeline momentum fuel investor interest.
Read More
J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J sees Innovative Medicines growth in 2025, fueled by oncology and immunology drugs, despite steep Stelara sales erosion.
Read More
J&J's experimental psoriasis drug shows promise against Bristol's treatment
Published: September 17, 2025 by: Reuters
Sentiment: Positive
Johnson & Johnson said on Wednesday its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb's Sotyktu in two late-stage head-to-head trials.
Read More
Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis
Published: September 17, 2025 by: PRNewsWire
Sentiment: Neutral
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed sustained skin clearance and favorable safety profile in both adults and adolescents at Week 52 in Phase 3 ICONIC-LEAD study Robust findings continue to demonstrate the potential of icotrokinra to disrupt the treatment paradigm to set a new standard for treating patients with moderate-to-severe plaque psoriasis SPRING HOUSE, Pa. , Sept. 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-ADVANCE 1 and 2 …
Read More
COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says
Published: September 12, 2025 by: Market Watch
Sentiment: Negative
Shares of companies that make COVID vaccines sank Friday, after a report raised fears that Trump administration health officials will blame the vaccines for some child deaths.
Read More
JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J seeks EMA's nod to icotrokinra for treating plaque psoriasis in adults and pediatric patients aged 12 years and older.
Read More
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Published: September 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Johnson & Johnson (JNJ) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson (NYSE:JNJ ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 11:30 AM EDT Company Participants Joaquin Duato - CEO & Chairman John Reed - Executive Vice President of Innovative Medicine, R&D Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Thanks for joining us, everybody.
Read More
5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Negative
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.
Read More
J&J Gains FDA Approval for Inlexzoh, Strengthens Pipeline Momentum
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J secures FDA approval for Inlexzoh, which boosts its Innovative Medicine pipeline and reinforces long-term growth momentum.
Read More
Are You Looking for a High-Growth Dividend Stock?
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Read More
Johnson & Johnson: JNJ Stock To $250?
Published: September 09, 2025 by: Forbes
Sentiment: Positive
Johnson & Johnson stock (NYSE: JNJ) has delivered a remarkable 24% return in 2025 even as the S&P 500 healthcare index declined 0.2%. This raises an important question: Is this outperformance grounded in durable business fundamentals, or is it a temporary market anomaly?
Read More
J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?
Published: September 08, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV and JNJ face patent cliffs but show resilience with strong pipelines, acquisitions and promising growth drivers.
Read More
Johnson & Johnson (JNJ) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)
Published: September 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson (NYSE:JNJ ) 2025 Wells Fargo Healthcare Conference September 3, 2025 11:50 AM EDT Company Participants Tim Schmid - Executive VP & Worldwide Chairman of MedTech Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Presentation Larry Biegelsen Senior Medical Device Equity Research Analyst Okay. Are we ready to go.
Read More
J&J Gears Up for Some Key New Drug Approvals and Launches
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ believes 10 of its new products and pipeline candidates can deliver peak sales of $5 billion, including Talvey, Tecvayli, Imaavy, Caplyta and others.
Read More
J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
JNJ halts Imaavy's rheumatoid arthritis program after trial results showed no added benefit over existing therapy.
Read More
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
2 High-Conviction Picks For 7.73% Growth And 4.22% Yield Within A Dividend Portfolio
Published: August 26, 2025 by: Seeking Alpha
Sentiment: Positive
Through our latest additions of Deutsche Post and Meta Platforms to The Dividend Income Accelerator Portfolio, we have increased the portfolio's sector diversification and global exposure. In addition to that, we have increased the portfolio's potential for dividend growth and capital appreciation. Our portfolio balances income and dividend growth, reflected in the portfolio's Weighted Average Yield on Cost [TTM] of 4.22% and 5-Year Weighted Average Dividend Growth Rate [CAGR] of 7.73%.
Read More
J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?
Published: August 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson stock surges above key moving averages as strong results, raised guidance and growth prospects fuel momentum.
Read More
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Read More
4 Medical Devices Behemoths to Buy Amid Extensive AI Applications
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Positive
AI-driven innovations in medical devices are fueling growth for BSX, JNJ, GEHC and TEM.
Read More
A new pharma factory shows how hard it could be for drugmakers to outrun Trump's tariffs
Published: August 21, 2025 by: CNBC
Sentiment: Positive
Fujifilm Biotechnologies will open a new biologics manufacturing plant in the U.S. this fall, with Regeneron and Johnson & Johnson as the initial customers. The Holly Springs, North Carolina, site is five years and $3.2 billion in the making.
Read More
Johnson & Johnson announces $2 billion investment to boost U.S. manufacturing as tariffs loom
Published: August 21, 2025 by: Fast Company
Sentiment: Positive
Johnson & Johnson said on Thursday it would invest $2 billion in North Carolina as it aims to expand its U.S. manufacturing presence amid looming drug import duties proposed by President Donald Trump's administration.
Read More
Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?
Published: August 21, 2025 by: Zacks Investment Research
Sentiment: Negative
J&J battles Stelara losses, talc lawsuits, tariffs and China headwinds while banking on growth plans and new launches to stay resilient.
Read More
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Published: August 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Joaquin Duato
- Employees 138100